Search Within

Neeta Pandit-Taskar

  1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (51)
  2. Meeting Abstract (44)
  3. Review (1)
Groups
  1. Department of Medicine (96)
  2. Molecular Imaging and Therapy Service (96)
  3. Radiology, Department of (96)
  4. Solid Tumor Oncology Division (96)
  5. GSK Faculty (67)
  6. Genitourinary Oncology Service (52)

More Groups

People
  1. Steven Larson (46)
  2. Michael Morris (45)
  3. Joseph O'Donoghue (44)
  4. Jorge Carrasquillo (40)
  5. Howard Scher (32)
  6. Serge Lyashchenko (30)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (3)
  4. 2022 (8)
  5. 2021 (4)
  6. 2020 (5)

More Years

Publications
  1. Journal of Clinical Oncology (31)
  2. Journal of Nuclear Medicine (22)
  3. Clinical Cancer Research (8)
  4. European Journal of Nuclear Medicine and Molecular Imaging (7)
  5. Journal for ImmunoTherapy of Cancer (3)
  6. Cancer Research (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (31)
  2. Society of Nuclear Medicine (22)
  3. Springer (13)
  4. American Association for Cancer Research (12)
  5. Elsevier Inc. (7)
  6. Biomed Central Ltd (3)

More Publishers

Results (96)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • STARLITE 2: Phase 2 study of nivolumab plus (177)Lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Feasibility, safety, and biodistribution of 18F-BMS-986229 PET in patients with esophagogastric (EG) cancer
    Meeting Abstract

    Cytryn, S.; Lumish, M.; Paroder, V.; Philemond, S.; Lewis, J.; Lyashchenko, S.; Janjigian, Y.; Pandit-Taskar, N.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • 1(8)F-FDG PET/CT for post-treatment surveillance imaging of patients with stage III Merkel cell carcinoma
    Journal Article

    Mahajan, S.; Barker, C. A.; Mauguen, A.; D’Angelo, S. P.; Yeh, R.; Pandit-Taskar, N.
    Journal of Nuclear Medicine (2022)

    Fulltext@MSK | Save
  • CD8-targeted PET imaging of tumor-infiltrating T cells in patients with cancer: A phase I first-in-humans study of (89)Zr-Df-IAB22M2C, a radiolabeled anti-CD8 minibody
    Journal Article

    Farwell, M. D.; Gamache, R. F.; Babazada, H.; Hellmann, M. D.; Harding, J. J.; Korn, R.; Mascioni, A.; Le, W.; Wilson, I.; Gordon, M. S.; more...
    Journal of Nuclear Medicine (2022)

    Fulltext@MSK | Save
  • Intraperitoneal pretargeted radioimmunotherapy for colorectal peritoneal carcinomatosis
    Journal Article

    Chandler, C. S.; Bell, M. M.; Chung, S. K.; Veach, D. R.; Fung, E. K.; Punzalan, B.; Burnes Vargas, D.; Patel, M.; Xu, H.; Guo, H. F.; more...
    Molecular Cancer Therapeutics (2022)

    Fulltext@MSK | Save
  • Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Walch, H. S.; Ptashkin, R.; Sabwa, S.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Imaging HER2-positive metastatic esophagogastric cancer with (89)Zr-trastuzumab PET and (18)F-FDG PET
    Meeting Abstract

    Lumish, M. A.; Maron, S. B.; Paroder, V.; Philemond, S.; O'Donoghue, J. A.; Schoder, H.; Lewis, J. S.; Janjigian, Y. Y.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase II, nonrandomized open trial assessing pain efficacy with radium-223 in symptomatic metastatic castration-resistant prostate cancer
    Journal Article

    McHugh, D.; Tagawa, S.; Moryl, N.; Milowsky, M.; Heller, G.; Osborne, J.; Rathkopf, D.; Basch, E.; Pandit-Taskar, N.; Morris, M. J.
    Clinical Genitourinary Cancer (2021)

    Fulltext@MSK | Save
  • Pretherapeutic first-in-human targeting trial of anti-hK2 antibody h11B6: A potential molecular vector for alpha-particle radioimmunotherapy
    Meeting Abstract

    Morris, M. J.; O' Donoghue, J. A.; Chetty, D.; Max, S.; Wanik, D.; Russell, M.; Nyima, T.; Avadhani, A. N.; Divgi, C. R.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • CD8 PET imaging of tumor infiltrating T cells in advanced solid tumors: A phase I first-in-human study of 89Zr-IAB22M2C, a radiolabeled anti-CD8 minibody
    Meeting Abstract

    Farwell, M.; Gamache, R.; Pandit-Taskar, N.; Postow, M.; Gordon, M.; Wilson, I.; Mascioni, A.; Wu, A.; Le, W.; Weiss, A.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save